Abstract: The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified virus and polynucleotides are also provided.
Type:
Grant
Filed:
March 30, 2009
Date of Patent:
March 6, 2012
Assignee:
Pfizer Inc.
Inventors:
Dongwan Yoo, Changhee Lee, Jay Gregory Calvert, Siao-Kun Welch
Abstract: The invention relates to compounds of the formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
Type:
Grant
Filed:
May 8, 2007
Date of Patent:
June 8, 2010
Assignee:
Pfizer Inc.
Inventors:
Hengmiao Cheng, Jingrong Jean Cui, Jacqui Elizabeth Hoffman, Lei Jia, Mary Catherine Johnson, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Bich Tran-Dubé
Abstract: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.
Type:
Grant
Filed:
May 2, 2006
Date of Patent:
March 9, 2010
Assignee:
Warner-Lambert Company LLC
Inventors:
Stephen Douglas Barrett, Victor Fedij, Lain-Yen Hu, Donna M. Iula, Bruce A. Lefker, Raj Kumar Raheja, Karen Sexton, Jennifer Ann Van Camp
Abstract: The invention relates to compounds of the formula 1 or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof, wherein L, R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating abnormal cell growth, such as cancer in a mammal by administering the compounds of formula 1.
Type:
Grant
Filed:
May 27, 2005
Date of Patent:
September 29, 2009
Assignee:
Pfizer Inc.
Inventors:
Matthew A. Marx, Jinshan Chen, Susan LaGreca
Abstract: The present invention relates to pyrrole substituted-2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
Type:
Grant
Filed:
September 6, 2006
Date of Patent:
August 11, 2009
Assignees:
Sugen, Inc., Pharmacia & Upjohn Co.
Inventors:
Peng Cho Tang, Todd Anthony Miller, Xiaoyuan Li, Connie Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
Abstract: This invention provides substituted pyrimido-pyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis, as well as angiogenesis and atherosclerosis. The invention compounds have Formula I: where W is NH, S, SO, or SO2, R1 includes alkyl, cycloalkyl, phenyl, substituted phenyl, heteroaryl and substituted heteroaryl; R2 includes alkyl, cycloalkyl, phenyl and substituted phenyl; R3 includes alkyl and aryl such as phenyl and substituted phenyl; R8 and R9 include hydrogen and alkyl, and the pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical formulations comprising a compound of Formula I together with a pharmaceutically acceptable carrier, diluent, or excipient therefor, and a method for treating angiogenesis using said compounds.
Type:
Grant
Filed:
May 10, 1999
Date of Patent:
March 10, 2009
Assignee:
Warner Lambert Company
Inventors:
Ellen Myra Dobrusin, James Marino Hamby, James Bernard Kramer, Mel Conrad Schroeder, Howard Daniel Hollis Showalter, Peter Toogood, Susanne A. Trumpp-Kallmeyer
Abstract: The present invention relates to compounds of the Formula wherein R1, R3, R4, R5, R6, R7 and R8 are as defined. Compounds of the Formula I have activity inhibiting production of A?-peptide. The invention also relates to pharmaceutical compositions and methods of treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
Abstract: The invention relates to biocatalytic methods for preparing enantiomerically pure stereoisomers of 1-(2,6-dichloro-3-fluorophenyl)ethanol. Disclosed are methods of preparation of the desired (S)-enantiomer, which methods are based on a combination of enzymatic resolution, chemical esterification and chemical hydrolysis with inversion of 1-(2,6-dichloro-3-fluorophenyl)ethyl esters or stereoselective bio-reduction of 2,6-dichloro-3-fluoro-acetophenone with a biocatalyst such as an enzyme or a microorganism. The chiral (S)-enantiomer can be used in the synthesis of certain enantiomerically enriched, ether linked 2-aminopyridine compounds that potently inhibit auto-phosphorylation of human heptocyte growth factor receptor.
Type:
Grant
Filed:
August 26, 2005
Date of Patent:
December 16, 2008
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Pei-Pei Kung, Carlos Martinez, Junhua Tao
Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers. The current invention relates to the making and using of such compounds.
Type:
Grant
Filed:
June 23, 2006
Date of Patent:
December 9, 2008
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Eugene Rui, Fen Wang, Yong Wang, Jinjiang Zhu
Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
Type:
Grant
Filed:
April 25, 2006
Date of Patent:
November 18, 2008
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Christopher Todd Bauer, Maureen Jeri Bourner, Melanie Boyle, Gerald Fries Casperson, David William Griggs, Richard David Head, William Dean Joy, Richard Allen Mazzarella, Ralph Raymond Minter, Mark Allen Moffat, Barrett Richard Thiele, Todd Lee Vanarsdale
Abstract: The invention relates to compounds of the formula 1 or a pharmaceutically acceptable salt, prodrug or hydrates thereof, wherein X, L, R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.
Type:
Grant
Filed:
November 16, 2004
Date of Patent:
October 14, 2008
Inventors:
Jinshan Chen, Matthew A. Marx, Susan D. LaGreca, Matthew D. Wessel
Abstract: The present invention provides crystals, and compositions thereof, wherein the crystals include a malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide. Methods of preparing such crystals are also disclosed.
Type:
Grant
Filed:
April 26, 2007
Date of Patent:
October 14, 2008
Assignee:
Pharmacia & Upjohn Company
Inventors:
Michael Hawley, Thomas J. Fleck, Stephen P. Prescott, Mark T. Maloney
Abstract: The present invention provides a method of treating hypertension, liver failure, loss of patency of ductus arteriosus, glaucoma or ocular hypertension in a patient, comprising administering to the patient a therapeutically effective amount of a selective EP4 receptor agonist of Formula I or a prodrug thereof, a pharmaceutically acceptable salt of the selective EP4 receptor agonist or prodrug or a stereoisomer or diastereomeric mixture of the EP4 receptor agonist, prodrug or salt, wherein the variables X, Z, Q, , and R2 are as defined in the specification.
Type:
Grant
Filed:
March 11, 2003
Date of Patent:
August 19, 2008
Assignee:
Pfizer Inc.
Inventors:
Kimberly O. Cameron, Bruce A. Lefker, Delvin R. Knight, Jr.
Abstract: Disclosed are polymorphs of the isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.
Type:
Grant
Filed:
July 6, 2004
Date of Patent:
March 18, 2008
Assignee:
Warner-Lambert Company LLC
Inventors:
Vladimar G. Beylin, Anthony Clyde Blackburn, David Thomas Erdman, Peter Laurence Toogood
Abstract: This invention relates to a new and convergent route to small molecule inhibitors of poly(ADP-ribose) polymerase, such as 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, via a key Sonogashira coupling reaction and a CuI-promoted indole formation.
Type:
Grant
Filed:
September 21, 2005
Date of Patent:
January 29, 2008
Assignees:
Agouron Pharmaceuticals, Inc., Cancer Research Technology Ltd.
Abstract: The present invention relates to novel polymorphic and amorphous forms of a phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
Type:
Grant
Filed:
September 21, 2005
Date of Patent:
September 11, 2007
Assignees:
Agouron Pharmaceuticals, Inc., Cancer Research Technology Ltd.
Inventors:
Jia Liu, Naresh Nayyar, Ming Guo, Zhen-Ping Wu, Bennett Chaplin Borer, Aparna Nadig Srirangam, Mark Bryan Mitchell, Yi Li, Jan-Jon Chu
Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts.
Abstract: The present invention relates to (2-oxindol-3-ylidenyl)acetic acid derivatives which modulate the activity of protein kinases and are therefore useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.